$USNU
Elite Health Systems Inc.

2024 Q1 Form 10-K Financial Statement

#000114036124018303 Filed on April 05, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $476.0K $243.0K $765.0K
YoY Change 266.15% -52.17% -44.81%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $476.0K $243.0K $765.0K
YoY Change 266.15% -52.17% -44.81%
Operating Profit -$476.0K -$765.0K
YoY Change 266.15% -44.81%
Interest Expense $1.000K $215.0K $2.000K
YoY Change -66.67% -81.14%
% of Operating Profit
Other Income/Expense, Net $1.000K -$51.00K
YoY Change -66.67% -65.31%
Pretax Income -$475.0K -$28.00K -$816.0K
YoY Change 274.02% -104.43% -46.77%
Income Tax -$163.0K $0.00 $0.00
% Of Pretax Income
Net Earnings -$312.0K -$146.0K -$816.0K
YoY Change 188.89% -128.91% -38.97%
Net Earnings / Revenue
Basic Earnings Per Share -$0.03 -$0.09
Diluted Earnings Per Share -$0.03 -$0.01 -$0.17
COMMON SHARES
Basic Shares Outstanding 13.30M 9.285M
Diluted Shares Outstanding 11.90M 9.285M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.750M $466.0K $466.0K
YoY Change 36.61% -69.68% -69.68%
Cash & Equivalents $1.750M $466.0K $466.0K
Short-Term Investments
Other Short-Term Assets $56.00K $61.00K $61.00K
YoY Change 194.74% 238.89% 238.89%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables
Total Short-Term Assets $1.806M $527.0K $527.0K
YoY Change 38.92% -66.11% -66.11%
LONG-TERM ASSETS
Property, Plant & Equipment $80.00K $85.00K $85.00K
YoY Change 700.0% 325.0% 325.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $191.0K $189.0K $189.0K
YoY Change 39.42% 20.38% 20.38%
Other Assets $714.0K $709.0K $520.0K
YoY Change 157.76% 312.21% 3366.67%
Total Long-Term Assets $794.0K $794.0K $794.0K
YoY Change 176.66% 313.54% 313.54%
TOTAL ASSETS
Total Short-Term Assets $1.806M $527.0K $527.0K
Total Long-Term Assets $794.0K $794.0K $794.0K
Total Assets $2.600M $1.321M $1.321M
YoY Change 63.83% -24.38% -24.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $75.00K $59.00K $59.00K
YoY Change 15.38% -31.4% -31.4%
Accrued Expenses $27.00K $27.00K $27.00K
YoY Change 125.0% 17.39% 17.39%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.202M $607.0K $607.0K
YoY Change 791.5% 116.79% 116.79%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $65.00K $69.00K $69.00K
YoY Change 490.91% 527.27% 527.27%
Total Long-Term Liabilities $65.00K $69.00K $69.00K
YoY Change 490.91% 527.27% 527.27%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.202M $607.0K $607.0K
Total Long-Term Liabilities $65.00K $69.00K $69.00K
Total Liabilities $2.267M $676.0K $676.0K
YoY Change 778.68% 132.3% 33.07%
SHAREHOLDERS EQUITY
Retained Earnings -$2.702M -$2.390M
YoY Change 48.62% 39.77%
Common Stock $3.035M $3.035M
YoY Change 2.92% 2.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $333.0K $645.0K $645.0K
YoY Change
Total Liabilities & Shareholders Equity $2.600M $1.321M $1.321M
YoY Change 63.83% -24.38% -24.38%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$312.0K -$146.0K -$816.0K
YoY Change 188.89% -128.91% -38.97%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$461.0K -$761.0K -$891.0K
YoY Change 254.62% 179.78% -36.94%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 -$54.00K -$180.0K
YoY Change -100.0% -104.66% -123.32%
Cash From Investing Activities $0.00 -$54.00K -$180.0K
YoY Change -100.0% -104.66% -123.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.745M 0.000 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -461.0K -761.0K -891.0K
Cash From Investing Activities 0.000 -54.00K -180.0K
Cash From Financing Activities 1.745M 0.000 0.000
Net Change In Cash 1.284M -815.0K -1.071M
YoY Change -601.56% -191.99% 67.08%
FREE CASH FLOW
Cash From Operating Activities -$461.0K -$761.0K -$891.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
61000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
18000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
527000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1555000
CY2023Q4 us-gaap Equity Method Investments
EquityMethodInvestments
189000
CY2022Q4 us-gaap Equity Method Investments
EquityMethodInvestments
157000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
709000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
172000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
85000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
85000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20000
CY2023Q4 us-gaap Assets
Assets
1321000
CY2022Q4 us-gaap Assets
Assets
1747000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
27000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
23000
CY2023Q4 us-gaap Liabilities
Liabilities
676000
CY2022Q4 us-gaap Liabilities
Liabilities
291000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
78000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2942000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2871000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2390000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1710000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
645000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1239000
CY2023Q4 us-gaap Minority Interest
MinorityInterest
0
CY2022Q4 us-gaap Minority Interest
MinorityInterest
217000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
645000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1456000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1321000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<div><span style="font-size: 10pt;"> </span> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"> <tr> <td style="width: 27pt; vertical-align: top; font-weight: bold;">[14]</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-weight: bold;">Estimates and assumptions:</div> </td> </tr> </table> <div><span style="font-size: 10pt;"> </span></div> <div><span style="font-size: 10pt;"><br/> </span> </div> <div><span style="font-size: 10pt;"> </span></div> <div style="text-align: justify; margin-left: 27pt; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.</div>
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1537000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
59000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
86000
CY2023Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
166000
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
171000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
607000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
280000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
58000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2023Q4 usnu Amount Of Guarantee Obligations Noncurrent
AmountOfGuaranteeObligationsNoncurrent
11000
CY2022Q4 usnu Amount Of Guarantee Obligations Noncurrent
AmountOfGuaranteeObligationsNoncurrent
11000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9284924
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9284924
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7792185
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7792185
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
93000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2023 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
765000
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1386000
CY2023 us-gaap Operating Expenses
OperatingExpenses
765000
CY2022 us-gaap Operating Expenses
OperatingExpenses
1386000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-765000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-1386000
CY2023 us-gaap Interest Expense
InterestExpense
2000
CY2022 us-gaap Interest Expense
InterestExpense
0
CY2023 usnu Income Loss From Loans To Unconsolidated Entities
IncomeLossFromLoansToUnconsolidatedEntities
-47000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-51000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-147000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-816000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1533000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
39000
CY2023 us-gaap Profit Loss
ProfitLoss
-816000
CY2022 us-gaap Profit Loss
ProfitLoss
-1572000
CY2023 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
CY2022 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-235000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-816000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-1337000
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9284924
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9284924
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7842185
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7842185
CY2023 us-gaap Profit Loss
ProfitLoss
-816000
CY2022 us-gaap Profit Loss
ProfitLoss
-1572000
CY2023 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
20000
CY2023 us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
23000
CY2022 us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
11000
CY2023 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
315000
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0
CY2023 us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
-5000
CY2022 us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
-243000
CY2023 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
43000
CY2022 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-47000
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-27000
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-83000
CY2023 usnu Increase Decrease In Operating Lease Right Of Use Liability
IncreaseDecreaseInOperatingLeaseRightOfUseLiability
23000
CY2022 usnu Increase Decrease In Operating Lease Right Of Use Liability
IncreaseDecreaseInOperatingLeaseRightOfUseLiability
43000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-891000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1413000
CY2023 us-gaap Payments For Advance To Affiliate
PaymentsForAdvanceToAffiliate
604000
CY2023 us-gaap Payments For Proceeds From Loans Receivable
PaymentsForProceedsFromLoansReceivable
-69000
CY2022 us-gaap Payments For Proceeds From Loans Receivable
PaymentsForProceedsFromLoansReceivable
-274000
CY2022 usnu Income Loss From Equity Method Investments Net
IncomeLossFromEquityMethodInvestmentsNet
1244000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-180000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
772000
CY2023 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
0
CY2022 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
0
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1071000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-641000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1537000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2178000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
466000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1537000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
0
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
211000
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001089815
CY2023Q4 us-gaap Financing Receivable After Allowance For Credit Loss Noncurrent Related Party Type Extensible Enumeration
FinancingReceivableAfterAllowanceForCreditLossNoncurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q4 us-gaap Financing Receivable After Allowance For Credit Loss Noncurrent Related Party Type Extensible Enumeration
FinancingReceivableAfterAllowanceForCreditLossNoncurrentRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023 dei Auditor Firm
AuditorFirmId
3233
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
0-15586
CY2023 dei Entity Registrant Name
EntityRegistrantName
U.S. NeuroSurgical Holdings, Inc.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-5370333
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
1131 W 6th Street
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Ontario
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
91672
CY2023 dei City Area Code
CityAreaCode
949
CY2023 dei Local Phone Number
LocalPhoneNumber
249-1170
CY2023 dei Security12g Title
Security12gTitle
Common Stock, par value $.01 per share
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
710297
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13304924
CY2023 dei Auditor Name
AuditorName
Mercurius & Associates LLP
CY2023 dei Auditor Location
AuditorLocation
New Delhi, India
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
466000
CY2023Q4 us-gaap Financing Receivable Excluding Accrued Interest After Allowance For Credit Loss Noncurrent
FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossNoncurrent
520000
CY2022Q4 us-gaap Financing Receivable Excluding Accrued Interest After Allowance For Credit Loss Noncurrent
FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLossNoncurrent
15000
CY2023Q4 usnu Private Placement Advances Pending For Allotment
PrivatePlacementAdvancesPendingForAllotment
355000
CY2022Q4 usnu Private Placement Advances Pending For Allotment
PrivatePlacementAdvancesPendingForAllotment
0
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1747000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2022 usnu Income Loss From Loans To Unconsolidated Entities
IncomeLossFromLoansToUnconsolidatedEntities
-163000
CY2023 us-gaap Income Loss From Equity Method Investments Net Of Dividends Or Distributions
IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
-2000
CY2022 us-gaap Income Loss From Equity Method Investments Net Of Dividends Or Distributions
IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
16000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3028000
CY2022 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
0
CY2022 us-gaap Profit Loss
ProfitLoss
-1572000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1456000
CY2023 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
5000
CY2023 usnu Stock Issued During Period Value Pending Certification
StockIssuedDuringPeriodValuePendingCertification
81000
CY2023 usnu Movement From Noncontrolling Interest To Retained Earnings
MovementFromNoncontrollingInterestToRetainedEarnings
-81000
CY2023 us-gaap Profit Loss
ProfitLoss
-816000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
645000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
39000
CY2023 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
25000
CY2022 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-116000
CY2023 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
5000
CY2022 us-gaap Payments For Advance To Affiliate
PaymentsForAdvanceToAffiliate
744000
CY2023 us-gaap Payments For Proceeds From Businesses And Interest In Affiliates
PaymentsForProceedsFromBusinessesAndInterestInAffiliates
-57000
CY2022 us-gaap Payments For Proceeds From Businesses And Interest In Affiliates
PaymentsForProceedsFromBusinessesAndInterestInAffiliates
2000
CY2023 usnu Income Loss From Equity Method Investments Net
IncomeLossFromEquityMethodInvestmentsNet
-57000
CY2023 usnu Proceeds From Advances For The Sale Of Equity
ProceedsFromAdvancesForTheSaleOfEquity
355000
CY2022 usnu Proceeds From Advances For The Sale Of Equity
ProceedsFromAdvancesForTheSaleOfEquity
0
CY2023 us-gaap Interest Paid Net
InterestPaidNet
2000
CY2023 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2023 us-gaap Profit Loss
ProfitLoss
-816000
CY2022 us-gaap Profit Loss
ProfitLoss
-1572000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2390000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
466000
CY2023Q4 usnu Working Capital Deficit
WorkingCapitalDeficit
-80000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2023 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
0
CY2022 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
0
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0
CY2023 us-gaap Advertising Expense
AdvertisingExpense
0
CY2022 us-gaap Advertising Expense
AdvertisingExpense
0
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div><span style="font-size: 10pt;"> </span> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"> <tr> <td style="width: 27pt; vertical-align: top; font-weight: bold;">[16]</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-weight: bold;">Credit risk:</div> </td> </tr> </table> <div><span style="font-size: 10pt;"> </span></div> <div><span style="font-size: 10pt;"><br/> </span> </div> <div><span style="font-size: 10pt;"> </span></div> <div style="text-align: justify; margin-left: 25.2pt; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">At times, the Company may have cash and cash equivalents at a financial institution in excess of insured limits. The Company places its cash and cash equivalents with high credit quality financial institutions whose credit ratings are monitored by management to minimize credit risk. Accounts receivable consisted of amounts due from the medical centers. Historically, credit losses on accounts receivable have not been significant. <span style="font-size: 13.3333px; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">At December 31, 2020, substantially all of the Company’s accounts receivable were due from one customer, NYU</span>. </span><br/> </div>
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
85000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20000
CY2023Q4 usnu Total Leased Assets Operating And Financing
TotalLeasedAssetsOperatingAndFinancing
85000
CY2022Q4 usnu Total Leased Assets Operating And Financing
TotalLeasedAssetsOperatingAndFinancing
20000
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
0
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
0
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
27000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
23000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
58000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2023Q4 usnu Total Lease Liabilities Operating And Finance
TotalLeaseLiabilitiesOperatingAndFinance
85000
CY2022Q4 usnu Total Lease Liabilities Operating And Finance
TotalLeaseLiabilitiesOperatingAndFinance
23000
CY2023 us-gaap Lease Cost
LeaseCost
0
CY2022 us-gaap Lease Cost
LeaseCost
41000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
30000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
30000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
31000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
91000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
85000
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0414
CY2023 usnu Renovation Installation And Operation Agreement Period
RenovationInstallationAndOperationAgreementPeriod
P14Y
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9284924
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
39000
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
39000
CY2023 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2023 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2022 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
39000
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-159000
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-322000
CY2023 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-50000
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-101000
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
184000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
246000
CY2023 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
0
CY2022 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
0
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
25000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
216000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
39000
CY2023Q4 us-gaap Deferred Tax Assets Equity Method Investments
DeferredTaxAssetsEquityMethodInvestments
80000
CY2022Q4 us-gaap Deferred Tax Assets Equity Method Investments
DeferredTaxAssetsEquityMethodInvestments
654000
CY2023Q4 usnu Deferred Tax Assets Intangible Assets And Other Capitalized Costs
DeferredTaxAssetsIntangibleAssetsAndOtherCapitalizedCosts
0
CY2022Q4 usnu Deferred Tax Assets Intangible Assets And Other Capitalized Costs
DeferredTaxAssetsIntangibleAssetsAndOtherCapitalizedCosts
-1000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
959000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
344000
CY2023Q4 usnu Deferred Tax Assets Net Effect Of Conversion From Accrual Basis Of Accounting To Cash Basis
DeferredTaxAssetsNetEffectOfConversionFromAccrualBasisOfAccountingToCashBasis
2000
CY2022Q4 usnu Deferred Tax Assets Net Effect Of Conversion From Accrual Basis Of Accounting To Cash Basis
DeferredTaxAssetsNetEffectOfConversionFromAccrualBasisOfAccountingToCashBasis
19000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1041000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1016000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
0
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
0
CY2019 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
85000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
85000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
85000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
85000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
23000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20000
CY2023 us-gaap Operating Lease Expense
OperatingLeaseExpense
35000
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
41000
CY2023 us-gaap Malpractice Insurance Annual Coverage Limit
MalpracticeInsuranceAnnualCoverageLimit
3000000
CY2023Q4 usnu Private Placement Advances Pending For Allotment
PrivatePlacementAdvancesPendingForAllotment
355000
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001140361-24-018303-index-headers.html Edgar Link pending
0001140361-24-018303-index.html Edgar Link pending
0001140361-24-018303.txt Edgar Link pending
0001140361-24-018303-xbrl.zip Edgar Link pending
ef20015308_10k.htm Edgar Link pending
ef20015308_ex21-1.htm Edgar Link pending
ef20015308_ex31-1.htm Edgar Link pending
ef20015308_ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
usnu-20231231.xsd Edgar Link pending
usnu-20231231_cal.xml Edgar Link unprocessable
usnu-20231231_def.xml Edgar Link unprocessable
usnu-20231231_lab.xml Edgar Link unprocessable
usnu-20231231_pre.xml Edgar Link unprocessable
ef20015308_10k_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable